One of the most advanced cancer care centres in the state of Odisha, it is equipped with the latest technology and a highly experienced multi-disciplinary team of oncologists
Technology Development Board supports commercialisation of Metal Injection Molding of implants
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
It celebrated its 100th session as LPC-100 in association with Mundial Pharma
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
The FDA decision is primarily informed by the positive results of a proof-of-concept, Phase 2a study evaluating the safety, immunogenicity, and efficacy of a single dose of 120µg RSVpreF in a human viral challenge model in healthy adults 18 to 50 years of age
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
#BeTheChangeForTB is a public awareness initiative under the Corporate TB Pledge and aims to create a cadre of Youth Changemakers who can act as catalysts of change to help eliminate TB from India
Subscribe To Our Newsletter & Stay Updated
